Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Open enrollment with a later-stage pipeline tilt

According to ClinicalTrials.gov-derived indexes, Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany sits in the upper quartile of US sponsors by registered trial count (#2,913 of 15,742 sponsors by registered trial count).

4 total trials 1 currently recruiting later-stage tilt upper quartile by trial count

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany: 4 sponsored US clinical trials, 1 recruiting.

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany sponsors 4 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting. 3 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Generalized Myasthenia Gravis, with 1 trials.

Upper-quartile sponsor footprint

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany sits in the upper quartile of the sponsor corpus (#2,913 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Open and recent trials

4 total, page 1 of 1

RECRUITING Phase 3

Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)

NCT06463587
ACTIVE NOT RECRUITING Phase 2

The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE)

NCT05540327
TERMINATED Phase 3

Study of Evobrutinib in Participants With RMS (evolutionRMS 2)

NCT04338061
TERMINATED Phase 3

Study of Evobrutinib in Participants With RMS (evolutionRMS 1)

NCT04338022

Phase Distribution

PhaseTrial count
Phase 2 1
Phase 3 3

Therapeutic Areas

Generalized Myasthenia Gravis 1
Systemic Lupus Erythematosus 1

Where Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany enrollment is open (later-stage tilt)

1 recruiting of 4 indexed (25% open).

Phase mix: 3 late (III/IV) vs 1 early (I/II) (later-stage heavy).

Top condition: Generalized Myasthenia Gravis (1 trial), 1 other listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany: open-pipeline peers nationwide

Peers matched on 4 registered trials and 25% open enrollment, not the therapeutic-area sidebar.

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 3456789 0%20%40%60%80% Total trials Recruiting share Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany4D pharma60 Degrees PharmaceuticalsA2 BiotherapeuticsAbdul Latif Jameel Poverty Action LabAB ScienceAbbott Point of CareAccutar BiotechnologyAdrienne G. Waks
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 4 trials (± recruiting share)

Sponsors near 25% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany page

4 registered trials is a research-attention snapshot, not an endorsement of Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany or any single study.

  • 1 of Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Generalized Myasthenia Gravis is the condition Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Generalized Myasthenia Gravis trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany pipeline card: 4 registered trials from official public datasets.Report a data error.